EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial

Ann Rheum Dis. 2014 Feb;73(2):472-4. doi: 10.1136/annrheumdis-2013-203736. Epub 2013 Aug 12.

Authors

R V Moerman¹, S Arends, P M Meiners, E Brouwer, F K L Spijkervet, F G M Kroese, A Vissink, H Bootsma

Affiliation

¹ Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, , Groningen, The Netherlands.

PMID: 23940214
DOI: 10.1136/annrheumdis-2013-203736

No abstract available

Keywords: B cells; Disease Activity; SjÃgren's Syndrome.

Publication types

Letter
Randomized Controlled Trial

MeSH terms

Antibodies, Monoclonal, Murine-Derived / therapeutic use*
Double-Blind Method
Humans
Immunologic Factors / therapeutic use*
Rituximab
Severity of Illness Index*
Sjogren's Syndrome / drug therapy*
Treatment Outcome

Substances

Antibodies, Monoclonal, Murine-Derived
Immunologic Factors
Rituximab